Abstract
CLINICAL QUESTION: Is there any new knowledge about the pathogenesis and treatment of age-related macular degeneration (AMD)? RESULTS: We now understand better the biochemical and pathological pathways involved in the genesis of AMD. Treatment of exudative AMD is based on intravitreal injection of new antivascular endothelial growth factor drugs for which there does not yet exist a unique recognized strategy of administration. No therapies are actually available for atrophic AMD, despite some experimental new pharmacological approaches. IMPLEMENTATION: strategy of administration, safety of intravitreal injection.